The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma

被引:3
|
作者
Gergely, Lajos [1 ]
Udvardy, Miklos [1 ]
Illes, Arpad [1 ]
机构
[1] Univ Debrecen, Fac Med, Dept Hematol, Inst Internal Med, H-4032 Debrecen, Hungary
关键词
DLBCL; pathogenesis; B-Cell Receptor; microenvironment; pathogens; EBV; HHV8; HCV; HBV; HIV; retrovirus; helicobacter; campylobacter; HEPATITIS-C VIRUS; NON-HODGKIN-LYMPHOMA; CLINICOPATHOLOGICAL FEATURES; TISSUE LYMPHOMA; INFECTION; PREVALENCE; HIV; EXPRESSION; SURVIVAL; DLBCL;
D O I
10.3390/biomedicines12030648
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. The disease is very heterogeneous, with distinct genetic alterations in subtypes. The WHO 2022 5th edition classification identifies several minor groups of large B-cell lymphoma where the pathogenetic role of viruses (like EBV and HHV-8) is identified. Still, most cases fall into the group of DLBCL not otherwise specified (NOS). No review focuses only on this specific lymphoma type in the literature. The pathogenesis of this entity is still not fully understood, but several viruses and bacteria may have a role in the development of the disease. The authors review critical pathogenetic events in the development of DLBCL (NOS) and summarize the data available on several pathogenetic viruses and bacteria that have a proven or may have a potential role in the development of this lymphoma type. The possible role of B-cell receptor signaling in the microenvironment is also discussed. The causative role of the Epstein-Barr virus (EBV), human herpesvirus-8 (HHV-8), Hepatitis C virus (HCV), human immunodeficiency virus (HIV), Hepatitis B virus (HBV), and other viruses are explored. Bacterial infections, such as Helicobacter pylori, Campylobacter jejuni, Chlamydia psittaci, Borrelia burgdorferi, and other bacteria, are also reviewed.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Characterisation of immunogenotypes of diffuse large B-cell lymphoma
    Phang, Kean Chang
    Hussin, Noor Hamidah
    Rahman, Faridah Abdul
    Tizen, Nur Maya Sabrina
    Mansoor, Adnan
    Masir, Noraidah
    MALAYSIAN JOURNAL OF PATHOLOGY, 2019, 41 (02) : 101 - 124
  • [32] Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
    Autio, Matias
    Leivonen, Suvi-Katri
    Brueck, Oscar
    Mustjoki, Satu
    Jorgensen, Judit Meszaros
    Karjalainen-Lindsberg, Marja-Liisa
    Beiske, Klaus
    Holte, Harald
    Pellinen, Teijo
    Leppa, Sirpa
    HAEMATOLOGICA, 2021, 106 (03) : 718 - 729
  • [33] The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma
    Habbous, Steven
    Guo, Helen
    Beca, Jaclyn
    Dai, Wei Fang
    Isaranuwatchai, Wanrudee
    Cheung, Matthew
    Chan, Kelvin K. W.
    CANCER MEDICINE, 2020, 9 (19): : 7072 - 7082
  • [34] A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
    Chung, Clement
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2022, 12 : 99 - 106
  • [35] Pidilizumab in the treatment of diffuse large B-cell lymphoma
    Bryan, Locke J.
    Gordon, Leo I.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (09) : 1361 - 1368
  • [36] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
    Varma, Gaurav
    Goldstein, Jordan
    Advani, Ranjana H.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
  • [37] Low-dose radiotherapy in diffuse large B-cell lymphoma
    Furlan, Carlo
    Canzonieri, Vincenzo
    Spina, Michele
    Michieli, Mariagrazia
    Ermacora, Anna
    Maestro, Roberta
    Piccinin, Sara
    Bomben, Riccardo
    Dal Bo, Michele
    Trovo, Marco
    Gattei, Valter
    Tirelli, Umberto
    Franchin, Giovanni
    Bulian, Pietro
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 472 - 479
  • [38] Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma
    Shen, Rong
    Fu, Di
    Dong, Lei
    Zhang, Mu-Chen
    Shi, Qing
    Shi, Zi-Yang
    Cheng, Shu
    Wang, Li
    Xu, Peng-Peng
    Zhao, Wei-Li
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [39] Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
    Bartlett, Nancy L.
    Hahn, Uwe
    Kim, Won-Seog
    Fleury, Isabelle
    Laribi, Kamel
    Bergua, Juan-Miguel
    Bouabdallah, Krimo
    Forward, Nicholas
    Bijou, Fontanet
    Macdonald, David
    Portell, Craig A.
    Ghesquieres, Herve
    Nowakowski, Grzegorz
    Yasenchak, Christopher A.
    Patterson, Monica
    Ho, Linda
    Rustia, Evelyn
    Fanale, Michelle
    Jie, Fei
    Kim, Jeong-A
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09) : 1061 - 1072
  • [40] Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma
    Roschewski, Mark
    Phelan, James D.
    Wilson, Wyndham H.
    CANCER JOURNAL, 2020, 26 (03) : 195 - 205